MIT researchers have developed a once-a-week pill that gradually releases medication for schizophrenia, demonstrating effectiveness in a phase 3 clinical trial. The capsule maintains consistent drug levels, making it easier for patients to adhere to their treatment regimens compared to daily doses. The study's promising results could lead to FDA approval and expansion to other medications.